Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATL 1102

Drug Profile

ATL 1102

Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102

Latest Information Update: 28 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics; Childrens Hospital Los Angeles
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antisense oligonucleotides
  • Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Multiple sclerosis

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Multiple sclerosis
  • No development reported Asthma; Cancer
  • Discontinued Stem cell mobilisation; Vertigo

Most Recent Events

  • 21 May 2020 Antisense Therapeutics anticipates Scientific Guidance from EMA for its planned phase IIb trial in Duchenne muscular dystrophy in Europe and United Kingdom in mid-2020
  • 21 May 2020 Antisense Therapeutics plans to apply for Orphan Drug Designation for ATL 1102 for Duchenne muscular dystrophy in USA and European Union
  • 21 May 2020 Antisense Therapeutics plans to make a clinical trial application to regulatory authorities for a phase II trial in Duchenne muscular dystrophy in Europe and United Kingdom
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top